- Home
- EKSO vs ACXP Comparison
EKSO vs ACXP Comparison
Compare EKSO & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- ACXP
- Stock Information
- Founded
- EKSO 2005
- ACXP 2017
- Country
- EKSO United States
- ACXP United States
- Employees
- EKSO 66
- ACXP N/A
- Industry
- EKSO Medical/Dental Instruments
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- EKSO Health Care
- ACXP Health Care
- Exchange
- EKSO Nasdaq
- ACXP Nasdaq
- Market Cap
- EKSO 7.7M
- ACXP 8.4M
- IPO Year
- EKSO N/A
- ACXP 2021
- Fundamental
- Price
- EKSO $3.37
- ACXP $0.47
- Analyst Decision
- EKSO Strong Buy
- ACXP Strong Buy
- Analyst Count
- EKSO 2
- ACXP 2
- Target Price
- EKSO $37.50
- ACXP $10.00
- AVG Volume (30 Days)
- EKSO 264.7K
- ACXP 18.7M
- Earning Date
- EKSO 07-28-2025
- ACXP 08-08-2025
- Dividend Yield
- EKSO N/A
- ACXP N/A
- EPS Growth
- EKSO N/A
- ACXP N/A
- EPS
- EKSO N/A
- ACXP N/A
- Revenue
- EKSO $17,544,000.00
- ACXP N/A
- Revenue This Year
- EKSO $0.20
- ACXP N/A
- Revenue Next Year
- EKSO $42.29
- ACXP N/A
- P/E Ratio
- EKSO N/A
- ACXP N/A
- Revenue Growth
- EKSO N/A
- ACXP N/A
- 52 Week Low
- EKSO $2.73
- ACXP $0.30
- 52 Week High
- EKSO $22.95
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- EKSO 41.00
- ACXP 52.38
- Support Level
- EKSO $3.14
- ACXP $0.45
- Resistance Level
- EKSO $3.69
- ACXP $0.59
- Average True Range (ATR)
- EKSO 0.31
- ACXP 0.08
- MACD
- EKSO 0.09
- ACXP -0.01
- Stochastic Oscillator
- EKSO 59.81
- ACXP 27.06
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.